|
Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rhabdomyosarcomas are malignancies associated with a rhabdomyoblastic phenotype which can be demonstrated morphologically or by immunohistochemistry for MYOD1 and myogenin.
|
31696361 |
2020 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
|
29973406 |
2018 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There was a significant association between high myogenin expression and ARMSs and high MyoD1 expression and spindle cell/sclerosing RMSs.
|
30098515 |
2018 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Silencing JARID2 resulted in reduced cell proliferation coupled with myogenic differentiation, including increased expression of Myogenin (MYOG) and Myosin Light Chain (MYL1) in RMS cell lines representative of both the alveolar and embryonal subtypes.
|
23435416 |
2014 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amongst the transcripts differentially expressed in the RD cells, MYOD and MYOG (2 fold, p<0.05), and six MYOD downstream targets were up-regulated in RD but not C2C12 cells.
|
23717650 |
2013 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the chimera led to continuous expression of MYOD and MYOG-two myogenic markers that are overexpressed in rhabdomyosarcoma cells.
|
24089019 |
2013 |
|
Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression of Kirsten rat sarcoma viral oncogene [Kras(G12V)] and disruption of cyclin-dependent kinase inhibitor 2A (CDKN2A; p16p19) in prospectively isolated satellite cells gave rise to pleomorphic rhabdomyosarcomas (MyoD-, Myogenin- and Desmin-positive), whereas introduction of the same oncogenetic hits in nonmyogenic progenitors induced pleomorphic sarcomas lacking myogenic features.
|
22135462 |
2011 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed both rhabdomyosarcoma and rhabdomyosarcomatous areas of the urothelial carcinoma were positive for myogenin, negative for cytokeratin and chromogranin stains.
|
21762516 |
2011 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CARM1 activates myogenin gene via PCAF in the early differentiation of TPA-induced rhabdomyosarcoma-derived cells.
|
20213728 |
2010 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Strategies to increase myogenin expression and block IL-4 could simultaneously reduce growth and migration, and enhance terminal differentiation of rhabdomyosarcoma, thus contributing to the control of tumor growth and metastatic spread.
|
19372547 |
2009 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
A single tissue microarray containing 71 paraffin-embedded pediatric RMSs was immunostained with antibodies against p53, bcl-2, Ki-67, CD44, myogenin, and MyoD1.
|
18708938 |
2008 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective analysis, diffuse immunohistochemical reactivity for myogenin in RMS correlates with decreased RFI and OS, independent of histologic subtype, translocation status, tumor site, or stage.
|
18708938 |
2008 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Myogenin, in particular, was highly significant (P = 0.0003) in distinguishing RMS from UESL.
|
17378682 |
2007 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Sequential recruitment of PCAF and BRG1 contributes to myogenin activation in 12-O-tetradecanoylphorbol-13-acetate-induced early differentiation of rhabdomyosarcoma-derived cells.
|
17468105 |
2007 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis with a panel of antibodies including antibodies against myogenin and alpha-inhibin is very important to diagnose the rhabdomyosarcoma and to grade the SLCT accurately.
|
16979522 |
2006 |
|
Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is one of the pediatric small round blue cell tumors, characterized by strong membrane expression of CD99 in a chain-mail pattern and negativity for lymphoid (CD45), rhabdomyosarcoma (myogenin, desmin, actin) and neuroblastoma (neurofilament protein) markers.
|
16720851 |
2006 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the value of myogenin staining and molecular testing in the diagnosis of rhabdomyosarcoma, the authors examined 109 rhabdomyosarcoma samples (45 ARMS samples and 64 ERMS samples).
|
15536621 |
2004 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although the focal alveolar architecture and the primitive cytologic appearance of these hyalinizing RMS suggest a relationship with ARMS, the presence of abundant strap cells in one case, the predominant expression of MyoD1 rather than myogenin, and the absence of ARMS-associated fusions genes point more strongly toward a variant of ERMS.
|
12218574 |
2002 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, IGF1 does not enhance myogenin expression in Rhabdomyosarcoma-derived RD cells.
|
10973962 |
2000 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although staining for myogenin was observed in 22 of 26 rhabdomyosarcomas, all alveolar rhabdomyosarcomas (nine of nine) showed high levels of staining for myogenin, as defined by the frequency and intensity of staining of the tumor cells.
|
10666368 |
2000 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors conclude that mRNA of the fetal type AChR but not myogenin is a highly specific and sensitive target for the PCR-based diagnosis of RMS.
|
9836066 |
1998 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the regulatory-gene analyses indicated that these 2 sublines represented 2 distinct differentiation stages of myoblasts, and that MyoD1 and myogenin could serve as the lineage marker and the differentiation marker, respectively, of human rhabdomyosarcoma.
|
1313401 |
1992 |